"Would it make ABET a stand-alone kidney disease drug if the eGFR show statistically significant increases?"

Possibly. But the label would probably be limited to stage 3 CKD (eGFR 30-60) consistent with BETonMACE CKD sub-study. Use in more severe CKD would require safety and efficacy clinical trials first. Not all patients with stage 3 CKD are diabetic, recent ACS, low-HDL like in BETonMACE. In my opinion, ABET as a stand alone kidney disease drug shouldn't depend on these criteria....but it's not up to me. If the eligible patient population excludes these criteria, this would expand the eligible population. But if the label is restricted to BETonMACE criteria, then this would limit the population. Since we already know that there was incredible MACE reduction in BETonMACE patients w/ baseline eGFR<60, this would make a powerful drug that reduces MACE AND raises eGFR.

"Do we know of any other drug that has caused eGFR to go up statistically significantly?"

I don't know this answer off hand. I will let someone else address this.

BDAZ